Aim: Liver cirrhosis (LC) is the end stage of chronic liver disease. No definitive pharmacological treatment is currently available. We previously reported that thrombopoietin (TPO) promoted liver regeneration and improved liver cirrhosis by increasing platelet count. TPO is therefore considered to be a therapeutic agent for LC; however, it is unclear whether TPO has proliferative effects on hepatocellular carcinoma (HCC), which arises frequently in cirrhotic livers. In this study we examined the effects of TPO on growth of HCC.
Introduction
Liver cirrhosis (LC) is the end stage of chronic liver disease. It carries a poor prognosis, and liver transplantation remains the only curative option. However, there are difficulties associated with liver transplantation, including a shortage of donors, high cost, transplant rejection, and surgical complications. At present, no definitive pharmacological treatment for LC is available, thus increasing the need for development of effective therapeutic agents.
In our previous studies, we demonstrated that platelets promote liver regeneration in in vitro 1, 2 and in vivo 3, 4 models. We also revealed that platelets reduced liver fibrosis in vivo, and platelet-derived adenosine 5'-triphosphate suppressed activation of human hepatic stellate cells, which play a critical role in liver fibrosis. [5] [6] [7] Blood transfusion and splenectomy are the traditional methods used to increase platelet counts. However, these approaches are associated with various difficulties, such as high costs, short storage periods, and platelet transfusion refractoriness for transfusions, 8 and infection and thrombosis for splenectomies. 9 Thrombopoietin (TPO) can increase platelet counts independently of blood transfusions and splenectomies, and we therefore considered using TPO as a treatment for LC.
TPO is the major hematopoietic growth factor involved in the proliferation and 5 differentiation of megakaryocytes. 10 Hepatocytes are the primary site of TPO synthesis. 11, 12 The TPO receptor (TPO-R), myeloproliferative leukemia virus oncogene (MPL), is reported to be expressed in liver sinusoidal endothelial cells (LSECs) in mice and in liver progenitor cells in rats, and TPO promotes the proliferation of both cell types. 13, 14 Hepatocellular carcinoma (HCC) develops frequently in cirrhotic livers.
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HCC carries a poor prognosis, and it recurs at high rates even after treatment. Therefore, it is very important that therapeutic agents for LC have no proliferative effect on HCC.
It has been reported that TPO increases platelets in the short term clinical study which includes HCC patients. 16 However, there is no report of long term clinical study. Since the impact of TPO is unclear in this regard, this study examined the effects of TPO on the growth of HCC both in vitro and in vivo. polymerase chain reaction (RT-PCR). Liver sections of HCC from these patients were also collected and fixed in 10% buffered formalin for later immunohistological analyses.
The study was approved by the hospital ethics committee and informed consent was obtained from all patients. MPL expression was examined in 5 cancerous and 5 non-cancerous samples from patients with HCC and hepatitis C virus hepatitis, 3
cancerous and 3 non-cancerous samples from patients with HCC and hepatitis B virus hepatitis, and 6 normal liver samples from patients with metastatic tumors.
Cell culture
Human hepatoblastoma cell lines (HepG2, Hep3B), a human well-differentiated HCC cell line (Huh7), human primary hepatocytes, and an immortalized human hepatic stellate cell line (TWNT-1) were used in cell cultures. 
Western blot analysis of transcriptional factors
Huh7 cells or hepatocytes were precultured in 6-well plates. The medium was then changed to serum-free medium (2 mL/well), the cells were cultured for 2 h, and 25 ng/ml recombinant human TPO (Peprotech, Rocky Hill, NJ, USA) was then added to each well. Cells were harvested at 5, 10, 15, 30, and 60 min after the addition of TPO.
HepG2 and Hep3B cells without TPO were also harvested. For Western blot analysis, cell lysates were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Millipore). The following β-actin (4970) (Cell Signaling) was used as the endogenous control. The secondary antibody that we used was anti-rabbit immunoglobulin-G horseradish peroxidase-linked antibody (Cell Signaling).
Cell proliferation
A total of 3 × 10 3 Huh7 cells in 100 μl of DMEM medium supplemented with 10% FBS, and 1 × 10 4 hepatocytes in 100 μl of Williams' E medium supplemented with 10%
FBS, were seeded in 96-well plates. After incubation at 37 °C for 24 h, the medium was changed to serum-free medium and cells were cultured for an additional 2 h. Different concentrations of TPO were then added to each well. After incubation at 37 °C for 24 h, cell counts were evaluated using the Cell Counting Kit-8 (Dojin, Kumamoto, Japan) and DNA synthesis was evaluated using the bromodeoxyuridine (BrdU) assay kit (Roche 11 Diagnostics GmbH, Penzberg, Germany) according to the manufacturer's instructions.
Cell migration and invasion assays
Huh7 cells were assessed for their migration and invasion abilities using a 96-well cell migration assay kit (Cultrex; Trevigen, Gaithersburg, MD, USA) and 96-well collagen IV cell invasion assay kit (Cultrex; Trevigen). Briefly, to starve Huh7 cells, the cells at 80% confluence were incubated in serum-free DMEM medium for 24 h. The membranes of the upper chambers were coated with 50 μl of 0.1 × Collagen IV solution and incubated for 4 h at 37 °C in 5% CO 2 (this process was used only for the invasion assay 
Anti-apoptosis assay
A total of 1 × 10 4 Huh7 cells in 100 μl of DMEM medium supplemented with 10%
FBS were seeded in 96-well plates. After incubation at 37 °C for 24 h, the medium was changed to serum-free medium and cells were cultured for an additional 2 h. Different concentrations of TPO and 0.1 μM of staurosporine (Sigma) were then added to each well. After incubation at 37 °C for 24 h, cell counts were evaluated using the Cell Counting Kit-8.
Animals
Female BALB/c nude mice (aged 7-8 weeks, weighing approximately 20 g; CLEA Japan, Tokyo, Japan) were used in all experiments. Mice were maintained in a temperature-controlled room on a 12 h light-dark cycle, with free access to water and standard chow. Animals were divided into 2 groups: a control group (n = 9), consisting of mice treated with saline, and a TPO-treated group (n = 8), composed of mice treated with TPO. Animal experiments were carried out in a humane manner after receiving 
Induction of thrombocytosis
To investigate the dose effect on platelet count elevation, TPO was injected intraperitoneally at doses of 5, 10, 20, and 75 μg/kg body weight into 4 mice per group, 5 days before platelet evaluation. Because platelet counts were elevated sufficiently at a TPO dose of 20 μg/kg body weight, we carried out the following experiments at this dose. 19 Tumor tissue, fixed in 10% buffered formalin, was used for histological analyses. Samples were stained in hematoxylin-eosin.
Xenograft model of human HCC cells

Statistical analysis
All data are expressed as the means ± standard deviations of samples. Statistical analyses were carried out with the Mann-Whitney U-test and one-way ANOVA, and significant data were examined using the Bonferroni-Dunn multiple comparisons post hoc test. In all cases, p values less than 0.05 were considered significant.
Results
Human MPL expression in tissues and cells
There were no significant differences in the expression of MPL mRNA between cancerous and non-cancerous tissues. MPL expression in hepatitis tissue was significantly lower than that in normal liver (Fig. 1A) . MPL expression in hepatoma cell lines and various liver cell types were also examined using the RT-PCR technique. We used the total RNA of HepG2, Hep3B, Huh7, human primary hepatocytes, human primary LSECs, and TWNT-1. MPL expression was highest in primary hepatocytes.
Among the hepatoma cell lines, Huh7 showed the highest expression of MPL (Fig. 1B) .
Therefore, we chose Huh7 cells in subsequent experiments. MPL protein was detected in the HCC tissue by immunohistochemistry (Fig. 1C) , and in the hepatoma cell lines by Western blot analysis (Fig. 1D ).
Signal transduction in Huh7 and primary hepatocytes
In Huh7, the Akt pathway was activated within 5 min after the addition of TPO, while TPO did not activate the ERK1/2, STAT3, or STAT5 pathways. In hepatocytes, the ERK1/2 and Akt pathways were activated within 15 min after the addition of TPO; the STAT3 pathway was slightly activated within 5 min after the addition of TPO, but the 16 STAT5 pathway was not activated by TPO addition (Fig. 2) .
Effect of TPO on proliferation, migration, and invasion
Cell count did not change when Huh7 was incubated with TPO. DNA synthesis by Huh7 cells and hepatocytes was not changed by the addition of TPO (Figs. 3A, B) . The ability of Huh7 cells to migrate through uncoated porous filters (Fig. 3C ) or invade collagen IV-coated filters ( Fig. 3D ) in response to TPO was examined in a Boyden chamber. TPO did not promote the migration or invasion of Huh7.
Effect of TPO on anti-apoptosis
We evaluated downstream signals in the Akt pathway. No significant differences in levels of Bax, Bcl-2, and cleaved caspase-3 ( Fig. 4A) were observed with or without TPO. Next, we evaluated the anti-apoptotic effects of TPO after adding staurosporine to
Huh7 cells. No anti-apoptotic effects were observed, although apoptosis was induced in
Huh7 cells by staurosporine (Fig. 4B) .
Xenograft model
TPO showed a significant dose-dependent effect on platelet count elevation (Fig. 5A ). 
Discussion
Liver transplantation is currently the only effective treatment for LC. We previously reported that platelets are able to suppress hepatic fibrosis and promote liver regeneration. We plan to develop novel treatments for LC by using TPO to increase MPL was expressed in HCC but we considered the expression levels to be very low.
Erythropoietin (EPO) is a hematopoietic growth factor that demonstrates amino acid homology with TPO. 24 The expression of EPO receptor (EPOR) has been demonstrated in many cancer cell lines and in tumor tissues. 25, 26 EPO promotes angiogenesis and proliferation and inhibits the apoptosis of tumor cells. 27 However, 3 studies have shown that EPO has no proliferative effect on cancer cell lines. [28] [29] [30] The expression of EPOR in tumor cells, therefore, does not necessarily reflect their capacity to accelerate tumor growth, nor does it always have a deleterious effect in cancer patients. 25, 31 Given these facts about EPO, and that expression levels of TPO in tumors are much lower than that of EPOR, 23 we speculated that the effects of TPO on tumors are negligible. Additionally,
Wetzler et al. 32 showed that there was no correlation between MPL expression and functional response to TPO. 20 TPO is known to function as a growth factor in megakaryocytopoiesis and platelet production, and it has also been reported that TPO has proliferative effects on non-hematogenous cells, such as venous endothelial cells 33 , hepatic progenitor cells 14 , and LSECs 13 . The ability of TPO to stimulate the proliferation of these non-hematogenous cells plays an important role in angiogenesis, liver endothelial cell repair, and regeneration. 34 Acute myelogenous leukemia (AML) blast cells express MPL and its protein, and TPO exerts a proliferative effect on these cells. [35] [36] [37] Romanelli et al. 22 showed that the migratory activity of hepatoblastoma cells increased in the presence of TPO. We examined the ability of TPO to stimulate the migration and invasion of HepG2, but found that it did neither (data not shown). Furthermore, TPO affected neither DNA synthesis nor cell proliferation in an HCC cell line in our study.
It is known that TPO activates the Janus tyrosine kinase/STAT pathway, the mitogen-activated protein kinase pathway, and the phosphoinositide 3-kinase (PI3K)/Akt pathway. [38] [39] [40] PI3K/Akt constitutes an important pathway regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation, and cell growth. 41 Phosphorylated Akt activates glycogen synthase kinase 3β (GSK3β) by phosphorylation at serine-9, resulting in accumulation of β-catenin and cyclin D1 in the nucleus, which induces DNA synthesis and cellular mitosis of 21 hepatocytes. 42, 43 On the other hand, other downstream Akt factors play critical roles in liver regeneration by regulating cell growth along with activated GSK3β. [44] [45] [46] fragment. 39 The efficacy of eltrombopag in HCV-infected patients with thrombocytopenia before initiation of pegylated-interferon and ribavirin therapy has previously been reported. 48 However, careful management is necessary, because portal vein thrombosis has been reported as a complication of romiplostim. 49 In contrast to TPO, eltrombopag does not activate the PI3K/Akt pathway. 50 Another report showed that eltrombopag has no proliferative effect in myelodysplastic syndromes and AML patients, 51 but rather inhibits the proliferation of leukemia cell lines. 52 Thus, eltrombopag would be secure to the HCC and the use of this type of TPO-R agonist can be anticipated as a novel treatment for liver disease. indicate ratios compared to a 100% value for 0 ng/ml TPO.
Fig. 4. Effect of TPO on anti-apoptosis
Huh7 cells were harvested at 0, 5, 10, 15, 30, and 60 min after 25 ng/ml of TPO was added, and activation of Bax, Bcl-2, and cleaved caspase-3 was examined by Western blotting (A). Huh7 cells were cultured with TPO and staurosporine for 24 h, and the anti-apoptotic effect of TPO on Huh7 was evaluated using the Cell Counting Kit-8 (B). 34 Data are expressed as means ± SDs with n = 8 for each group. The values indicate ratios compared to a 100% value without TPO or staurosporine. 
